Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 13, 2022 08:00 ET | Source: Alpha Tau Medical Ltd.

Alpha Tau to Present at Biotech Showcase and Participate in LifeSci Advisors Corporate Access Event During J.P. Morgan Healthcare Conference in San Francisco in January 2023

JERUSALEM, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau," or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...
November 22, 2022 16:02 ET | Source: Alpha Tau Medical Ltd.

Alpha Tau Medical Announces Third Quarter 2022 Financial Results and Provides Corporate Update

JERUSALEM, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha...
November 09, 2022 08:00 ET | Source: Alpha Tau Medical Ltd.

Alpha Tau to Present at Upcoming November Investor Conferences

JERUSALEM, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...
October 21, 2022 16:01 ET | Source: Alpha Tau Medical Ltd.

Alpha Tau Announces Multiple Corporate Updates Ahead of 2022 Annual Meeting of the American Society for Radiation Oncology

- Medicines and Healthcare products Regulatory Agency of the United Kingdom approves clinical trial in squamous cell carcinoma of the vulva at Addenbrookes Hospital in Cambridge - - Health Canada...
September 08, 2022 16:05 ET | Source: Alpha Tau Medical Ltd.

Alpha Tau Announces the Acceptance in Major Peer-Reviewed Journals (International Journal of Radiation Oncology, Biology, Physics, and Frontiers in Oncology) of Two Landmark Pre-Clinical Studies Demonstrating Significant Potential Synergies Between the Alpha DaRT Treatment and Standard-of-Care Immunotherapy, Chemotherapy and Anti-Angiogenic Therapy

– Study on combination with anti-PD1 therapy published by International Journal of Radiation Oncology, Biology, Physics, known in the field as the Red Journal, the official journal of the American...
September 01, 2022 16:15 ET | Source: Alpha Tau Medical Ltd.

Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer

JERUSALEM, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that...
August 30, 2022 16:05 ET | Source: Alpha Tau Medical Ltd.

Alpha Tau Medical to Participate in Upcoming September Investor Conferences

JERUSALEM, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the...
August 25, 2022 16:05 ET | Source: Alpha Tau Medical Ltd.

Alpha Tau Medical Announces Second Quarter 2022 Financial Results and Provides Corporate Update

-Received FDA Conditional Investigational Device Exemption (IDE), whose conditions have since been satisfied, to initiate a pivotal trial of Alpha DaRT™ in recurrent cutaneous squamous cell carcinoma....
August 22, 2022 09:00 ET | Source: Alpha Tau Medical Ltd.

Alpha Tau and MIM Software Announce Collaboration for Alpha DaRT Treatment Planning

JERUSALEM and CLEVELAND, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Today, Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and...